OncoMatch/Clinical Trials/NCT04875611
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Is NCT04875611 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Opdivo for nasopharyngeal cancer.
Treatment: Opdivo — Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients disqualified from radical therapy . The total number of patients was estimated for 32.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Previous, documented failure on platinum-based chemotherapy or progression of the disease during platinum-based chemotherapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or anti-ICOS directed agent
Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent
Cannot have received: bone marrow or solid organ transplantation
Patient with prior bone marrow or solid organ transplantation.
Lab requirements
Blood counts
hemoglobin < 9 g/dl, platelets < 100 x 10^9 /L, ANC < 1.0 x 10^9 /L
Kidney function
eGFR < 30 ml/min/m2
Liver function
AST and/or ALT > 2.5 x ULN (> 5 x ULN in patients with documented liver metastases); total bilirubin > 1.5 x ULN (acceptable if direct bilirubin < 35%); albumin < 2.5 g/dL
Cardiac function
ejection fraction in echocardiography < 50%
Presence of renal insufficiency defined as eGFR < 30 ml/min/m2; Presence of liver disfunction, defined as level of AST and/or ALT > 2.5 x ULN (> 5 x ULN in patients with documented liver metastases); total bilirubin > 1.5 x ULN (acceptable if direct bilirubin < 35%) or albumin < 2.5 g/dL; Abnormalities in blood count such as: hemoglobin < 9 g/dl, platelets < 100 x 10^9 /L, ANC <1.0 x 10^9 /L; Ejection fraction in echocardiography < 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04875611 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1/PD-L2 or anti-ICOS directed agent, bone marrow or solid organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages